Base de dados : MEDLINE
Pesquisa : D02.033.100.624.675 [Categoria DeCS]
Referências encontradas : 152 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 16 ir para página                         

  1 / 152 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:22002742
[Au] Autor:Hayat S; Khalique G; Irfan M; Wani AS; Tripathi BN; Ahmad A
[Ad] Endereço:Plant Physiology Section, Department of Botany, Aligarh Muslim University, Aligarh, 202002, Uttar Pradesh, India. shayat@lycos.com
[Ti] Título:Physiological changes induced by chromium stress in plants: an overview.
[So] Source:Protoplasma;249(3):599-611, 2012 Jul.
[Is] ISSN:1615-6102
[Cp] País de publicação:Austria
[La] Idioma:eng
[Ab] Resumo:This article presents an overview of the mechanism of chromium (Cr) stress in plants. Toxic effects of Cr on plant growth and development depend primarily on its valence state. Cr(VI) is highly toxic and mobile whereas Cr(III) is less toxic. Cr-induced oxidative stress involves induction of lipid peroxidation in plants that cause severe damage to cell membranes which includes degradation of photosynthetic pigments causing deterioration in growth. The potential of plants with the adequacy to accumulate or to stabilize Cr compounds for bioremediation of Cr contamination has gained engrossment in recent years.
[Mh] Termos MeSH primário: Cromo/farmacologia
Fotossíntese/efeitos dos fármacos
Plantas/metabolismo
Poluentes do Solo/farmacologia
[Mh] Termos MeSH secundário: Antioxidantes/metabolismo
Cromo/metabolismo
Germinação/efeitos dos fármacos
Peroxidação de Lipídeos
Oxifedrina
Componentes Aéreos da Planta/efeitos dos fármacos
Componentes Aéreos da Planta/crescimento & desenvolvimento
Proteínas de Plantas/metabolismo
Raízes de Plantas/efeitos dos fármacos
Raízes de Plantas/crescimento & desenvolvimento
Plantas/efeitos dos fármacos
Plântulas/efeitos dos fármacos
Plântulas/crescimento & desenvolvimento
Poluentes do Solo/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antioxidants); 0 (Plant Proteins); 0 (Soil Pollutants); 0R0008Q3JB (Chromium); DWL616XF1K (Oxyfedrine)
[Em] Mês de entrada:1210
[Cu] Atualização por classe:171012
[Lr] Data última revisão:
171012
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:111018
[St] Status:MEDLINE
[do] DOI:10.1007/s00709-011-0331-0


  2 / 152 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:15802815
[Au] Autor:Mazumdar K; Dutta NK; Kumar KA; Dastidar SG
[Ad] Endereço:Division of Microbiology, Department of Pharmaceutical Technology, Jadavpur University.
[Ti] Título:In vitro and in vivo synergism between tetracycline and the cardiovascular agent oxyfedrine HCl against common bacterial strains.
[So] Source:Biol Pharm Bull;28(4):713-7, 2005 Apr.
[Is] ISSN:0918-6158
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:The cardiovascular drug oxyfedrine HCl revealed noteworthy in vitro antibacterial action against 501 strains of Gram positive and Gram negative bacteria. It also offered significant protection to mice challenged with a mouse-virulent bacterial strain. Prompted by such results, the present study was carried out to ascertain whether this drug could augment the efficiency of an antibiotic when used in combination with it. For this purpose, ten bacterial strains were selected, which were sensitive to oxyfedrine as well as to six antibiotics, like benzyl penicillin, chloramphenicol, ciprofloxacin, erythromycin, streptomycin and tetracycline. Distinct and statistically significant (p<0.01) synergism was observed between oxyfedrine and tetracycline by disc diffusion tests, compared with their individual effects. The fractional inhibitory concentration (FIC) index of this combination, evaluated by checkerboard analysis, was 0.37, which confirmed synergism between the pair. This synergistic drug duo was further dispensed to infected mice. The results of the mouse-protection tests advocated that the combination was significantly synergistic (p<0.0001), according to Student's 't' test. Hence, the capacity of extended antibiotic therapy in several microbial diseases may be improved with the help of this synergistic drug pair, and the study might throw light on newer directions to contest drug-resistant bacterial infections.
[Mh] Termos MeSH primário: Antibacterianos/farmacologia
Oxifedrina/farmacologia
Tetraciclina/farmacologia
[Mh] Termos MeSH secundário: Animais
Bactérias/efeitos dos fármacos
Sinergismo Farmacológico
Quimioterapia Combinada
Masculino
Camundongos
Testes de Sensibilidade Microbiana
Salmonelose Animal/tratamento farmacológico
Salmonella typhimurium/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); DWL616XF1K (Oxyfedrine); F8VB5M810T (Tetracycline)
[Em] Mês de entrada:0508
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:050402
[St] Status:MEDLINE


  3 / 152 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:15665959
[Au] Autor:Dzhanashiya PKh; Vladytskaya OV; Salibegashvili NV
[Ad] Endereço:Department of Visceral Diseases, Faculty for Medical Upgrading, Russian State Medical University, Moscow.
[Ti] Título:Efficiency and mechanisms of the antioxidant effect of standard therapy and refracterin in the treatment of chronic heart failure in elderly patients with postinfarction cardiosclerosis.
[So] Source:Bull Exp Biol Med;138(4):412-4, 2004 Oct.
[Is] ISSN:0007-4888
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Refracterin therapy of patients with chronic heart failure caused by coronary heart disease and postinfarction cardiosclerosis markedly promoted improvement in the pulmonary and systemic circulation in comparison with patients receiving traditional therapy. The mean functional class of chronic cardiac failure decreased by 43% under the effect of refracterin vs. 27% decrease in the group receiving traditional therapy. After 1-month refracterin course the end-systolic and end-diastolic sizes of the left ventricle decreased by 12 and 7%, respectively, ejection fraction increased by 7.2% in comparison with the initial level, total oxidant activity and MDA content in the plasma decreased significantly, while total antioxidant activity, catalase and SOD activities, cytochrome C, NADH, and NADPH levels increased. The prooxidant-antioxidant system was shifted towards antioxidants, which attests to activation of the defense and adaptive mechanisms after administration of refracterin, which is especially important in elderly patients with initially decreased reserve potentialities of the antioxidant defense system.
[Mh] Termos MeSH primário: Antioxidantes/uso terapêutico
Cardiotônicos/uso terapêutico
Insuficiência Cardíaca/tratamento farmacológico
Insuficiência Cardíaca/metabolismo
[Mh] Termos MeSH secundário: Acetildigoxinas/administração & dosagem
Idoso
Idoso de 80 Anos ou mais
Antioxidantes/administração & dosagem
Cardiotônicos/administração & dosagem
Citocromos c/administração & dosagem
Combinação de Medicamentos
Insuficiência Cardíaca/patologia
Seres Humanos
Inosina/administração & dosagem
Infarto do Miocárdio/tratamento farmacológico
Infarto do Miocárdio/metabolismo
Infarto do Miocárdio/patologia
NAD/administração & dosagem
Estresse Oxidativo/efeitos dos fármacos
Oxifedrina/administração & dosagem
Esclerose
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Acetyldigoxins); 0 (Antioxidants); 0 (Cardiotonic Agents); 0 (Drug Combinations); 0U46U6E8UK (NAD); 5A614L51CT (Inosine); 9007-43-6 (Cytochromes c); DWL616XF1K (Oxyfedrine)
[Em] Mês de entrada:0507
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:050125
[St] Status:MEDLINE


  4 / 152 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:15514727
[Au] Autor:Kanorskii SG; Galenko-Yaroshevskii PA; Zingilevskii KB
[Ad] Endereço:Krasnodar Research Center, Russian Academy of Medical Sciences, Administration of Krasnodar Krai; Krasnodar City Emergency Hospital.
[Ti] Título:Efficiency of refracterin in patients with chronic cardiac insufficiency caused by coronary heart disease.
[So] Source:Bull Exp Biol Med;138(1):67-9, 2004 Jul.
[Is] ISSN:0007-4888
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Composite preparation refracterin administered in a dose of 300 mg/day for 3 days in addition to routine therapy significantly improved the results of treatment of severe cardiac insufficiency of ischemic genesis compared to placebo. Improvement of clinical status of patients is determined by positive dynamics of systolic and diastolic functions of the left ventricle.
[Mh] Termos MeSH primário: Acetildigoxinas/uso terapêutico
Baixo Débito Cardíaco/tratamento farmacológico
Cardiotônicos/uso terapêutico
Doença das Coronárias/tratamento farmacológico
Citocromos c/uso terapêutico
Inosina/uso terapêutico
NAD/uso terapêutico
Oxifedrina/uso terapêutico
[Mh] Termos MeSH secundário: Idoso
Baixo Débito Cardíaco/etiologia
Doença Crônica
Doença das Coronárias/complicações
Combinação de Medicamentos
Ecocardiografia/efeitos dos fármacos
Feminino
Seres Humanos
Masculino
Meia-Idade
Sístole/efeitos dos fármacos
Resultado do Tratamento
Função Ventricular Esquerda/efeitos dos fármacos
[Pt] Tipo de publicação:CLINICAL TRIAL; COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Acetyldigoxins); 0 (Cardiotonic Agents); 0 (Drug Combinations); 0U46U6E8UK (NAD); 5A614L51CT (Inosine); 9007-43-6 (Cytochromes c); DWL616XF1K (Oxyfedrine)
[Em] Mês de entrada:0505
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:041030
[St] Status:MEDLINE


  5 / 152 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:14521236
[Au] Autor:Mazumdar K; Ganguly K; Kumar KA; Dutta NK; Chakrabarty AN; Dastidar SG
[Ad] Endereço:Division of Microbiology, Department of Pharmaceutical Technology, Jadavpur University, Calcutta 700 032, India.
[Ti] Título:Antimicrobial potentiality of a new non-antibiotic: the cardiovascular drug oxyfedrine hydrochloride.
[So] Source:Microbiol Res;158(3):259-64, 2003.
[Is] ISSN:0944-5013
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Ten cardiovascular drugs, having diverse pharmacological action, were screened for possible antimicrobial property against known eight sensitive bacteria, belonging to Gram positive and Gram negative types. Although five drugs failed to show antimicrobial activity and three had moderate antimicrobial action, oxyfedrine HCl and dobutamine were seen to possess pronounced antimicrobial property. Oxyfedrine was further tested in vitro against 471 strains of bacteria from two Gram positive and fourteen Gram negative genera. The minimum inhibitory concentration (MIC) of oxyfedrine was determined by agar dilution method, which ranged from 50-200 microg/ml in most of the strains, while some strains were inhibited at even lower concentrations. In animal experiments, this compound was capable of offering significant protection to Swiss strain of white mice, challenged with 50 median lethal dose (MLD) of a virulent strain of Salmonella typhimurium at concentrations of 15, 30 and 60 microg/mouse. The in vivo results were highly significant according to chi-square test.
[Mh] Termos MeSH primário: Antibacterianos/farmacologia
Fármacos Cardiovasculares/farmacologia
Bactérias Gram-Negativas/efeitos dos fármacos
Bactérias Gram-Positivas/efeitos dos fármacos
Oxifedrina/farmacologia
[Mh] Termos MeSH secundário: Animais
Cardiotônicos/farmacologia
Masculino
Camundongos
Testes de Sensibilidade Microbiana
Salmonelose Animal/tratamento farmacológico
Salmonella typhimurium/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Cardiotonic Agents); 0 (Cardiovascular Agents); DWL616XF1K (Oxyfedrine)
[Em] Mês de entrada:0311
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:031003
[St] Status:MEDLINE


  6 / 152 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:10498985
[Au] Autor:Karsanov NV; Sukoian GV; Dzhibgashvili IK; Tatulashvili DR; Gorelishvili II; Guchua EI
[Ti] Título:[The subcellular pathophysiology of heart failure due to toxic-allergic myocarditis and the action of refracterin on intracardiac hemodynamics and the functional state of the 3 subcellular cardiomyocyte systems responsible for the act of contraction-relaxation].
[Ti] Título:Subkletochnaia patofiziologiia nedostatochnosti serdtsa, obuslovennoi toksiko-allergicheskim miokarditom, i deistvie refrakterina na vnutriserdechnuiu gemodinamiku i funktsional'noe sostoianie trekh subkletochnykh sistem kardiomiotsita otvetstvennykh za akt sokrashchenie--rasslablenie..
[So] Source:Patol Fiziol Eksp Ter;(3):3-8, 1999 Jul-Sep.
[Is] ISSN:0031-2991
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:It is shown that cardiotropic drug refracterin promotes recovery of cardiac contraction and relaxation, their coordination destroyed in cardiac failure (CF) caused by 10-day toxico-allergic myocarditis (TAM). Pumping capacity of the heart returns to normal after normalization of functional activity of three systems of cardiomyocyte responsible for contraction-relaxation: contractile proteins, energy supply and calcium transport. The key process is refracterin-related reestablishment of normal content and proportion of adenyl nucleotides and creatininephosphate and regulation role of phosphorylation and energy of metabolic processes in the cells and their interaction. Thus, refracterin effectiveness lies in its ability to interfere in intracellular metabolic processes in the myocardium, to reestablish normal homeostasis of the systems responsible for contraction-relaxation function and eventually to remove left ventricular cardiac dysfunction.
[Mh] Termos MeSH primário: Acetildigoxinas/farmacologia
Fármacos Cardiovasculares/farmacologia
Grupo dos Citocromos c/farmacologia
Insuficiência Cardíaca/fisiopatologia
Coração/efeitos dos fármacos
Contração Miocárdica/efeitos dos fármacos
Miocardite/fisiopatologia
Miocárdio/ultraestrutura
Oxifedrina/farmacologia
[Mh] Termos MeSH secundário: Acetildigoxinas/uso terapêutico
Animais
Transporte Biológico/efeitos dos fármacos
Cálcio/metabolismo
Fármacos Cardiovasculares/uso terapêutico
Grupo dos Citocromos c/uso terapêutico
Combinação de Medicamentos
Avaliação Pré-Clínica de Medicamentos
Coração/fisiopatologia
Insuficiência Cardíaca/tratamento farmacológico
Insuficiência Cardíaca/etiologia
Hemodinâmica/efeitos dos fármacos
Proteínas Musculares/efeitos dos fármacos
Proteínas Musculares/fisiologia
Contração Miocárdica/fisiologia
Miocardite/complicações
Miocardite/tratamento farmacológico
Miocárdio/metabolismo
Oxifedrina/uso terapêutico
Coelhos
Fatores de Tempo
[Pt] Tipo de publicação:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Acetyldigoxins); 0 (Cardiovascular Agents); 0 (Cytochrome c Group); 0 (Drug Combinations); 0 (Muscle Proteins); DWL616XF1K (Oxyfedrine); SY7Q814VUP (Calcium)
[Em] Mês de entrada:9910
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:990928
[St] Status:MEDLINE


  7 / 152 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:9693495
[Au] Autor:Paleev NR; Sanina NP; Paleev FN; Pronina VP; Sukoian GV; Karsanov NV
[Ti] Título:[Chronic cardiac failure in noncoronarogenic myocardial diseases and refracterin effects].
[Ti] Título:Khronicheskaia serdechnaia nedostatochnost' pri nekoronarogennykh zabolevaniiakh miokarda i deistvie na nee refrakterina..
[So] Source:Klin Med (Mosk);76(6):21-6, 1998.
[Is] ISSN:0023-2149
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Mh] Termos MeSH primário: Cardiomiopatias/complicações
Insuficiência Cardíaca/etiologia
[Mh] Termos MeSH secundário: Adolescente
Agonistas Adrenérgicos beta/uso terapêutico
Adulto
Idoso
Biópsia
Cardiomiopatias/tratamento farmacológico
Cardiomiopatias/patologia
Doença Crônica
Grupo dos Citocromos c/farmacologia
Grupo dos Citocromos c/uso terapêutico
Combinação de Medicamentos
Feminino
Insuficiência Cardíaca/tratamento farmacológico
Insuficiência Cardíaca/patologia
Seres Humanos
Inosina/farmacologia
Inosina/uso terapêutico
Masculino
Meia-Idade
NAD/farmacologia
NAD/uso terapêutico
Oxifedrina/farmacologia
Oxifedrina/uso terapêutico
Resultado do Tratamento
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenergic beta-Agonists); 0 (Cytochrome c Group); 0 (Drug Combinations); 0U46U6E8UK (NAD); 5A614L51CT (Inosine); DWL616XF1K (Oxyfedrine)
[Em] Mês de entrada:9809
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:980807
[St] Status:MEDLINE


  8 / 152 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:9673832
[Au] Autor:Kirsten R; Nelson K; Kirsten D; Heintz B
[Ad] Endereço:Department of Clinical Pharmacology, University of Frankfurt, Germany.
[Ti] Título:Clinical pharmacokinetics of vasodilators. Part II.
[So] Source:Clin Pharmacokinet;35(1):9-36, 1998 Jul.
[Is] ISSN:0312-5963
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:Stimulating cardiac beta 1-adrenoceptors with oxyfedrine causes dilatation of coronary vessels and positive inotropic effects on the myocardium. beta 1-adrenergic agonists increase coronary blood flow in nonstenotic and stenotic vessels. The main indication for the use of the phosphodiesterase inhibitors pamrinone, mirinone, enoximone and piroximone is acute treatment of severe congestive heart failure. Theophylline is indicated for the treatment of asthma, chronic obstructive pulmonary disease, apnea in preterm infants ans sleep apnea syndrome. Severe arterial occlusive disease associated with atherosclerosis can be beneficially affected by elcosanoids. These drugs must be administered parenterally and have a half-life of only a few minutes. Sublingual or buccal preparations of nitrates are the only prompt method (within 1 or 2 min) of terminating anginal pain, except for biting nifedipine capsules. The short half-life (about 2.5 min) of nitroglycerin (glyceryl trinitrate) makes long term therapy impossible. Tolerance is a problem encountered with longer-acting nitric oxide donors. Knowledge of the pharmacokinetic properties of vasodilating drugs can prevent a too sudden and severe blood pressure decrease in patients with chronic hypertension. In considering the administration of a second dose, or another drug, the time necessary for the initially administered drug to reach maximal efficacy should be taken into account. In hypertensive emergencies urapidil, sodium nitroprusside, nitroglycerin, hydralazine and phentolamine are the drugs of choice, with the addition of beta-blockers during catecholamine crisis or dissecting aortic aneurysm. Childhood hypertension is most often treated with angiotensin-converting enzyme (ACE) inhibitors or calcium antagonists, primarily nifedipine. Because of the teratogenic risk involved with ACE inhibitors, extreme caution must be exercised when prescribing for adolescent females. The propagation of health benefits to breast-fed infants, combined with more women delaying pregnancy until their fourth decade, has entailed an increase in the need for hypertension management during lactation. Low dose hydrochlorothiazide, propranolol, nifedipine and enalapril or captopril do not pose enough of a risk of preclude breastfeeding in this group. The most frequently used antihypertensive agents during pregnancy are methyldopa, labetalol and calcium channel antagonists. Methyldopa and beta-blockers are the drugs of choice for treating mild to moderate hypertension. Prazosin and hydralazine are used to treat moderate to severe hypertension and hydralazine, urapidil or labetalol are used to treat hypertensive emergencies. The use of overly aggressive antihypertensive therapy during pregnancy should be avoided so that adequate uteroplacental blood flow is maintained. Methyldopa is the only drug accepted for use during the first trimester of pregnancy.
[Mh] Termos MeSH primário: Vasodilatadores/farmacocinética
[Mh] Termos MeSH secundário: Antagonistas Adrenérgicos alfa/farmacocinética
Agonistas Adrenérgicos beta/farmacocinética
Alprostadil/farmacocinética
Amrinona/farmacocinética
Carbazóis/farmacocinética
Enoximona/farmacocinética
Feminino
Seres Humanos
Iloprosta/farmacocinética
Imidazóis/farmacocinética
Indoramina/farmacocinética
Dinitrato de Isossorbida/análogos & derivados
Dinitrato de Isossorbida/farmacocinética
Labetalol/farmacocinética
Milrinona
Molsidomina/farmacocinética
Nitroglicerina/farmacocinética
Nitroprussiato/farmacocinética
Oxifedrina/farmacocinética
Tetranitrato de Pentaeritritol/farmacocinética
Inibidores de Fosfodiesterase/farmacocinética
Piperazinas/farmacocinética
Prazosina/farmacocinética
Gravidez
Propanolaminas/farmacocinética
Piridonas/farmacocinética
Teofilina/farmacocinética
Trapidil/farmacocinética
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Adrenergic alpha-Antagonists); 0 (Adrenergic beta-Agonists); 0 (Carbazoles); 0 (Imidazoles); 0 (Phosphodiesterase Inhibitors); 0 (Piperazines); 0 (Propanolamines); 0 (Pyridones); 0 (Vasodilator Agents); 0K47UL67F2 (carvedilol); 0Z802HMY7H (Indoramin); 10L39TRG1Z (Pentaerythritol Tetranitrate); 169D1260KM (Nitroprusside); 2VSD0380YB (piroximone); A78GF17HJS (urapidil); C137DTR5RG (Theophylline); C7Z4ITI7L7 (Enoximone); CC6X0L40GW (moxonidine); D46583G77X (Molsidomine); DWL616XF1K (Oxyfedrine); EYG5Y6355E (Trapidil); F5TD010360 (Alprostadil); G59M7S0WS3 (Nitroglycerin); IA7306519N (Isosorbide Dinitrate); JED5K35YGL (Iloprost); JU9YAX04C7 (Milrinone); JUT23379TN (Amrinone); LX1OH63030 (isosorbide-5-mononitrate); R5H8897N95 (Labetalol); XM03YJ541D (Prazosin)
[Em] Mês de entrada:9809
[Cu] Atualização por classe:171113
[Lr] Data última revisão:
171113
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:980723
[St] Status:MEDLINE


  9 / 152 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:9567753
[Au] Autor:Maulik SK; Seth SD; Maulik M; Manchanda SC
[Ad] Endereço:Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, India.
[Ti] Título:Oxyfedrine in myocardial stunning.
[So] Source:Indian J Exp Biol;35(11):1214-7, 1997 Nov.
[Is] ISSN:0019-5189
[Cp] País de publicação:India
[La] Idioma:eng
[Ab] Resumo:Effect of oxyfedrine (OXF)(1 mg/kg) administered just before reperfusion (post-treatment) was investigated in a canine model of myocardial stunning. In the saline-treated animals, myocardial stunning was evidenced by fall in MAP, decrease in LV peak (+) dP/dt, rise in LVEDP and incomplete regeneration of myocardial ATP, after reperfusion. OXF was found to be effective in preventing the haemodynamic and metabolic changes associated with myocardial stunning.
[Mh] Termos MeSH primário: Cardiotônicos/uso terapêutico
Miocárdio Atordoado/tratamento farmacológico
Oxifedrina/uso terapêutico
[Mh] Termos MeSH secundário: Animais
Cães
Coração/efeitos dos fármacos
Hemodinâmica/efeitos dos fármacos
Miocárdio/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Cardiotonic Agents); DWL616XF1K (Oxyfedrine)
[Em] Mês de entrada:9805
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:980506
[St] Status:MEDLINE


  10 / 152 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:8817463
[Au] Autor:Qu YZ; Wang YE; Li XX
[Ad] Endereço:Department of Pharmacology, Inner Mongolia Medical College, Huhhot, China.
[Ti] Título:Effects of thiofedrine on platelet aggregation, thromboxane B2 and 6-keto-PGF1 alpha in rats.
[So] Source:Methods Find Exp Clin Pharmacol;18(5):297-300, 1996 Jun.
[Is] ISSN:0379-0355
[Cp] País de publicação:Spain
[La] Idioma:eng
[Ab] Resumo:Thiofedrine inhibited rat platelet aggregation and intraplatelet thromboxane B2 (TxB2) generation induced by arachidonic acid. The IC50 values were 0.18 and 0.21 mmol/l, respectively. Thiofedrine, 1.25-5.00 mg/kg i.v., showed a significant inhibition of rat platelet aggregation and intraplatelet TxB2 generation induced by arachidonic acid, with ID50 values of 2.4 and 3.3 mg/kg. Thiofedrine, 0.5-2.0 mg/kg i.v., reduced TxB2 generation but increased 6-keto-PGF1 alpha formation in rat plasma.
[Mh] Termos MeSH primário: 6-Cetoprostaglandina F1 alfa/sangue
Antitrombinas/farmacologia
Oxifedrina/análogos & derivados
Inibidores da Agregação de Plaquetas/farmacologia
Agregação Plaquetária/efeitos dos fármacos
Tromboxano B2/biossíntese
[Mh] Termos MeSH secundário: Animais
Ácido Araquidônico/farmacologia
Depressão Química
Feminino
Masculino
Oxifedrina/farmacologia
Ratos
Ratos Wistar
Tromboxano B2/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antithrombins); 0 (Platelet Aggregation Inhibitors); 27YG812J1I (Arachidonic Acid); 28745-68-8 (thiofedrine); 54397-85-2 (Thromboxane B2); 58962-34-8 (6-Ketoprostaglandin F1 alpha); DWL616XF1K (Oxyfedrine)
[Em] Mês de entrada:9611
[Cu] Atualização por classe:131121
[Lr] Data última revisão:
131121
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:960601
[St] Status:MEDLINE



página 1 de 16 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde